AlveoliX AG
AlveoliX AG is a Swiss biotech tools company that develops proprietary organ-on-chip and lung-on-chip in vitro systems with breathing-motion simulation, selling hardware, consumables, and disease-specific biomodels to pharmaceutical, biotech, CRO, and academic customers for preclinical drug testing.
- Company typePrivate
- Founded2019
- HeadquartersBerne, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What AlveoliX AG does
AlveoliX AG is a Swiss biotech tools company founded in 2019 as a spin-off from the University of Bern's ARTORG Center for Biomedical Engineering Research, specializing in organ-on-chip and barrier-on-chip in vitro systems for pharmaceutical drug discovery and preclinical testing. The company's core product platforms are the AXLung-on-Chip System and the AXBarrier-on-Chip System, built around a proprietary AX12 microfluidic chip with an ultrathin 3.5µm elastic membrane and connected via the AXDock to the AXExchanger (fluid control with TEER measurement) and the AXBreather (pneumatic controller that simulates 12 cycles/min breathing motion with 8% linear strain). On top of this hardware, AlveoliX sells AXBiomodels (pre-developed monoculture, co-culture, immune, inflammation, and fibrosis models) and, since June 2023, AX Cells-on-Chip pre-seeded consumables. Its core technology is protected by a granted US patent on the breathing-motion lung-on-chip design and benefits from the regulatory tailwind of the FDA Modernization Act 2.0, which enables organ-on-chip data as standalone preclinical evidence.
The company operates a direct B2B sales model targeting pharmaceutical and biotech companies, contract research organizations, and academic research institutions, supported by participation in major scientific conferences (SOT, EUROTOX, ERS, EUROoCS) and a partnership-driven approach for technology validation and disease-specific applications. Named enterprise customers include Roche (Biochip Storming AX collaboration) and CSL Behring (sitem-insel hub partnership for lung disease translation), with academic collaborators including the Francis Crick Institute for iPSC-derived lung infection models and the University of Bern / Inselspital as founding academic partners. Revenue is generated through hardware sales of the chip ecosystem, consumables (chips, AX Cells-on-Chip), and professional services for custom biomodel development and research collaborations.
AlveoliX is headquartered in Bern, Switzerland (Freiburgstrasse 3, near sitem-insel) with a production site in Biel/Bienne at the Switzerland Innovation Park, and serves primarily European customers with selective North American outreach. Funding has come almost entirely from non-dilutive grants (Eurostars, Innosuisse, SNSF BRIDGE Discovery) rather than priced venture capital, and the company is led by co-CEOs Dr. Nina Hobi and Dr. Janick Stucki, with Prof. Olivier Guenat, the technology originator, remaining on the Board. In 2026, AlveoliX co-founded IAMPS, the first European industry association for microphysiological systems providers, alongside eight peer companies, positioning the firm as a standards-setter in the emerging organ-on-chip category.
AlveoliX AG firmographics
Firmographics- Name
- AlveoliX AG
- Legal name
- AlveoliX AG
- Website
- https://alveolix.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AlveoliX AG is a Swiss biotech tools company that develops proprietary organ-on-chip and lung-on-chip in vitro systems with breathing-motion simulation, selling hardware, consumables, and disease-specific biomodels to pharmaceutical, biotech, CRO, and academic customers for preclinical drug testing.
- Ownership category
- akta.pro rank
AlveoliX AG industry classification
Industry- Product category
- Organ-on-Chip / Microphysiological Systems
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)
- akta.pro secondary industries
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), Cell-Based & Potency Assays (Bioassays) (HLAGADAH), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG)
Keywords
Where AlveoliX AG is headquartered
LocationHeadquarters
- HQ city
- Berne
- HQ country
- Switzerland
- HQ region
- Europe
Offices2 records
Markets served
AlveoliX AG business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- Organ-on-Chip Systems and Products: Sale of AX12 chips, AXLung-on-Chip System, AXBarrier-on-Chip System and related consumables for drug discovery and preclinical research.
- AXBiomodels and Custom Model Development: Provision of disease-specific biomodels and custom model development services for pharmaceutical and biotech company research needs.
- Research Collaborations: Collaborative research projects with academic institutions and pharmaceutical partners for specific disease applications.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
AlveoliX AG product offering
Product offeringCore offering
AlveoliX AG designs, manufactures, and sells proprietary organ-on-chip platforms — primarily the AXLung-on-Chip and AXBarrier-on-Chip Systems — that recreate human lung and barrier microenvironments in vitro with mechanical breathing simulation. The company supplies the AX12 chip, AXDock, AXExchanger, and AXBreather hardware, together with AXBiomodels (pre-developed toxicity, inflammation, and fibrosis models) and the AX Cells-on-Chip line of pre-seeded chips, for pharmaceutical and biotech drug discovery and preclinical testing applications.
Product overview
AlveoliX AG offers a modular organ-on-chip product ecosystem centered on two core platforms: the AXLung-on-Chip System and the AXBarrier-on-Chip System. The AXLung-on-Chip System includes the AX12 chip (96-well format with 6 independent units), AXDock, AXExchanger, and AXBreather components that work together to recreate breathing lung models with ultrathin membranes (3.5µm) and cyclic strain (12 cycles/min, 8% linear strain). The AXBarrier-on-Chip System provides barrier modeling capability. Both platforms use the AXBiomodels library (monoculture, co-culture, immuno, inflammation, fibrosis models) for specific testing applications. The AX Cells-on-Chip line extends the portfolio with pre-seeded cells for standardized workflows. The systems are designed for drug discovery, preclinical toxicity and efficacy testing, and are compatible with standard laboratory equipment and readouts including TEER, ELISA, rtPCR, and flow cytometry.
Differentiator
Problem solved
Functional benefit
Products and services
- AXLung-on-Chip System A lung-on-chip system that replicates the human lung microenvironment with breathing motion, including the AX12 chip (ultrathin 3.5µm membrane with 3µm pores), AXDock connection hub, AXExchanger for fluid control, and AXBreather for pneumatic breathing simulation (12 cycles/min, 8% linear strain). Designed for pharmaceutical and biotech drug discovery and preclinical studies.
- AXBarrier-on-Chip System A barrier-on-chip platform that recreates the air-blood barrier with human-derived cells for in vitro toxicity and efficacy testing in drug discovery and preclinical studies, supporting mono-culture, co-culture, and immune cell integration.
- AX Cells-on-Chip Product line of cells pre-seeded on the AX chip platform, providing standardized, ready-to-use in vitro testing models for drug testing applications.
- AXBiomodels Disease-specific in vitro biomodels including toxicity models (monoculture, co-culture, immuno), efficacy models (inflammation, fibrosis), and custom model development services for pharmaceutical and biotech company research needs.
Quantifiable outcome
- 87% sensitivity in predicting drug-induced liver injury (FDA ISTAND pilot program for comparable MPS technologies)
Companies that use AlveoliX AG
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
AlveoliX AG technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature5 records
AlveoliX AG partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core, major and minor.
- European WiFIX Consortium PartnerscoreEuropean consortium awarded EUR 1 million Eurostars grant to develop Nexopore, a wireless electroporation-based system for delivering nucleic acid therapeutics. AlveoliX is part of this consortium focused on overcoming delivery challenges for nucleic acid therapeutics.
- InSCREENeX GmbHcoreCo-developed new immortalized alveolar cell line (AXiAECs) combining InSCREENeX's CI-SCREEN methodology with AlveoliX's organ-on-chip technology. Cells derived from primary alveolar epithelial cells feature tight barrier formation and robust marker expression.
- EpiEndo PharmaceuticalscoreEPIColiX project under Eurostars program developing gut-on-chip model for drug testing. AlveoliX developing colon epithelium model for screening EpiEndo's lead compounds for ulcerative colitis treatment.
- PANC-CKI ConsortiummajorAlveoliX part of consortium led by CasInvent Pharma awarded €4M Eurostars grant for pancreatic cancer research. Consortium achieved top ranking in Czech Republic, Switzerland, and overall.
- RochemajorHosted first Biochip Storming AX event with Roche Basel to address challenges and opportunities of organ-on-chip technology within drug development pipeline.
- CSL BehringcoreCSL Behring, Insel Gruppe and AlveoliX joined forces within sitem-insel AG's hub to improve translation and find new treatments for lung diseases.
- Francis Crick InstitutecoreJoint development of first human lung-on-chip model using stem cells from a single donor, capable of simulating breathing motions and replicating lung disease for personalized medicine applications. Tested with tuberculosis infection.
- University of Bern / ARTORG CentercoreLong-term academic partnership for organ-on-chip technology development. Founding relationship where technology originated from Prof. Olivier Guenat's research group.
- InselspitalcoreSwitzerland's largest hospital group, partner in lung research and clinical translation of organ-on-chip technology for patient benefit.
- IAMPS (Industry Alliance for Microphysiological Systems)coreCo-founded with 8 other European MPS companies (BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, TissUse) as the world's first industry association dedicated to representing microphysiological systems providers. Association aims to increase regulatory acceptance, create data-sharing platforms, and advance device standardization.
- BRIDGE Discovery Project ConsortiummajorSNSF/Innosuisse funded project with Université de Neuchâtel, CHUV, SIB, and SiMPLInext SA to establish novel solution for antibiotic resistance using environmental interference to fight lung fungal infections.
- NA3RsC (North American 3Rs Collaborative)minorPart of MPS initiative working to increase industry adoption and regulatory acceptance of MPS technologies with the goal of refining, reducing, and replacing research animals.
Scale indicators5 records
Recent moves6 records
Expansion highlights7 records
AlveoliX AG competitors and assessment
Company assessmentDirect peers
- Emulate Inc. US-based organ-on-chip company commercializing the Emulate Liver-Chip and other organ models for pharma R&D. Direct competitor to AlveoliX's AXLung/AXBarrier-on-Chip platforms with overlapping target customers in big pharma and similar microfluidic chip-plus-instrument business model.
- Dynamic42 GmbH: German organ-on-chip company developing immune-system and infection-on-chip models for pharma and academic research. Direct competitor, fellow IAMPS co-founder, and comparable European early-commercial MPS provider.
- CN Bio Innovations: UK-based organ-on-chip company commercializing the PhysioMimix platform for liver and lung MPS models. Direct competitor with comparable single- and multi-organ chip offerings aimed at pharma toxicology and disease modeling.
- NETRI: French organ-on-chip company industrializing microfluidic neural and organ-on-chip devices for pharma screening. Direct competitor in MPS hardware, fellow IAMPS co-founder, with overlapping target use cases in neurological and systemic drug testing.
- BiomimX: Italian organ-on-chip startup focused on heart and vascular MPS models using beating-cardiac technology. Direct competitor and fellow IAMPS co-founder with similar early-stage European MPS positioning.
- MIMETAS: Dutch organ-on-chip company offering the OrganoPlate platform for high-throughput 3D tissue models. Direct competitor targeting pharmaceutical drug discovery and toxicology with comparable organ-on-chip hardware, consumables, and custom model services.
- React4Life: Italian organ-on-chip company commercializing the MIVO (Multi-In-Vitro-Organ) platform for fluid-dynamic tissue models. Direct competitor in MPS-based preclinical testing, fellow IAMPS co-founder, with comparable European pharma and academic customer base.
- TissUse GmbH: German multi-organ-on-chip company offering the HUMIMIC chip systems for substance testing. Direct competitor in MPS hardware with overlapping pharma customer base and fellow IAMPS co-founder.
- InSphero: Swiss 3D cell culture and organ-on-chip company providing liver, islet, and tumor microtissues for drug safety/efficacy testing. Direct competitor in MPS-based preclinical tools, fellow IAMPS co-founder, and similarly Swiss-based with overlapping pharma customers.
Regional players
- Cherry Biotech: French organ-on-chip company offering the Chipster platform with temperature-controlled microfluidic MPS systems for academic and pharma research. Comparable European MPS provider serving overlapping applications in cell-based preclinical testing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
AlveoliX AG social profiles
Digital presenceAlveoliX AG financial estimates
Financial estimateRevenue estimate
Valuation estimate
AlveoliX AG leadership team
Management profileNumber of profiles
Profiles4 records
AlveoliX AG funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AlveoliX AG M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AlveoliX AG
What does AlveoliX AG do?
AlveoliX AG designs, manufactures, and sells proprietary organ-on-chip platforms — primarily the AXLung-on-Chip and AXBarrier-on-Chip Systems — that recreate human lung and barrier microenvironments in vitro with mechanical breathing simulation. The company supplies the AX12 chip, AXDock, AXExchanger, and AXBreather hardware, together with AXBiomodels (pre-developed toxicity, inflammation, and fibrosis models) and the AX Cells-on-Chip line of pre-seeded chips, for pharmaceutical and biotech drug discovery and preclinical testing applications.
Is AlveoliX AG a public or private company?
AlveoliX AG is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AlveoliX AG founded?
AlveoliX AG was founded in 2019. It employs 11 to 50 people.
Where is AlveoliX AG based?
AlveoliX AG is headquartered in Berne, Switzerland, in the Europe region.
How does AlveoliX AG make money?
Three revenue lines are on record. Organ-on-Chip Systems and Products are the primary driver. The others are AXBiomodels and Custom Model Development and research Collaborations.
Who are AlveoliX AG's main competitors?
Direct peers on record are Emulate Inc., Dynamic42 GmbH, CN Bio Innovations, NETRI, BiomimX, MIMETAS, React4Life, TissUse GmbH and InSphero. Cherry Biotech is listed as a regional player.
Does AlveoliX AG have an API?
No public API is recorded for AlveoliX AG.
What industry is AlveoliX AG in?
AlveoliX AG's product category is Organ-on-Chip / Microphysiological Systems. Its primary akta.pro industry code is HLAAAGAD, Organoids & Organ-on-Chip (regenerative models), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 334516 and its SIC code is 3841.